Entering a New Realm of Treating MOGAD: Insights on Improvements in Diagnosis, Therapeutics, and Emerging Research
Neurologists Benjamin Greenberg, MD, and Jeffrey Bennett, MD, PhD, delved into the complexities of diagnosing and treating MOG antibody-associated disease (MOGAD). The duo share insight about the evolving diagnostic process and the current treatment landscape, emphasizing both pharmacologic and non-pharmacologic approaches. Further, they discussed ongoing research efforts and drug developments aimed at addressing unmet needs in managing this challenging condition.
EP. 1: Navigating MOGAD Diagnosis: Clinical Insights and Key Considerations
September 16th 2024In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]
EP. 2: Continuing Evolution of MOGAD Diagnosis, Remaining Questions in Antibody Titer Testing
September 16th 2024In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]
EP. 5: Unmet Needs and Challenges Across Pediatric and Adult MOGAD Populations
September 18th 2024The pair of neurologists provided clinical insight on a number of lingering non-treatment unmet needs for patients with MOGAD, including improved care for pediatric patients and underreported complications like sleep disturbances and genitourinary issues in adults. [WATCH TIME: 5 minutes]
EP. 6: Advancing MOGAD Research: Predictive Markers, Immune Remodeling, and Future Therapies
September 18th 2024In this episode, a pair of neuroimmune experts discussed some of the emerging research for patients with MOGAD, highlighting the need for immunological markers, remodeling therapies, and enhancements to diagnostic criteria. [WATCH TIME: 5 minutes]
